ORF
MCID: CNT001
MIFTS: 31

Contagious Pustular Dermatitis (ORF)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Contagious Pustular Dermatitis

MalaCards integrated aliases for Contagious Pustular Dermatitis:

Name: Contagious Pustular Dermatitis 12 15
Ecthyma, Contagious 12 44 73
Ecthyma Contagiosum 12
Thistle Disease 12
Scabby Mouth 12
Sheep Pox 12
Orf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8771
ICD10 33 B08.02
ICD9CM 35 051.2
MeSH 44 D004474
SNOMED-CT 68 74050005
UMLS 73 C0013570

Summaries for Contagious Pustular Dermatitis

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Orf virus, which is transmitted by contact with infected or recently vaccinated animals, or transmitted by fomites carrying the virus. The infection has symptom lesions on the finger, hand, arm, face, and penis.

MalaCards based summary : Contagious Pustular Dermatitis, also known as ecthyma, contagious, is related to milker's nodule and dermatitis, and has symptoms including lesions on the finger An important gene associated with Contagious Pustular Dermatitis is FOXK1 (Forkhead Box K1). The drugs Methylphenidate and Amphetamine have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Orf is an exanthemous disease caused by a parapox virus and occurring primarily in sheep and goats. It... more...

Related Diseases for Contagious Pustular Dermatitis

Diseases related to Contagious Pustular Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 milker's nodule 11.4
2 dermatitis 10.9
3 skin disease 10.4
4 erythema multiforme 10.3
5 ecthyma 10.3
6 human herpesvirus 8 10.2
7 vaccinia 10.1
8 severe acute respiratory syndrome 10.1
9 viral infectious disease 10.1
10 hepatitis 10.0
11 sarcoma 10.0
12 epidermolysis bullosa 10.0
13 epidermolysis bullosa acquisita 10.0
14 platelet membrane fluidity 9.9
15 hepatitis e 9.9
16 bronchitis 9.9
17 influenza 9.9
18 candida glabrata 9.9
19 kaposi sarcoma 9.8
20 marfan syndrome 9.8
21 6-phosphogluconolactonase deficiency 9.8
22 myeloma, multiple 9.8
23 dermatitis, atopic 9.8
24 hepatitis c virus 9.8
25 infantile liver failure syndrome 1 9.8
26 al-raqad syndrome 9.8
27 acute liver failure 9.8
28 hepatitis b 9.8
29 systemic scleroderma 9.8
30 erysipeloid 9.8
31 laryngotracheitis 9.8
32 spastic ataxia 9.8
33 mumps 9.8
34 rabies 9.8
35 chlamydia 9.8
36 diarrhea 9.8
37 hepatitis c 9.8
38 hemorrhagic disease 9.8
39 leptospirosis 9.8
40 gastroenteritis 9.8
41 papilloma 9.8
42 pyoderma 9.8
43 hypotrichosis 9.8
44 borna disease 9.8
45 cutaneous anthrax 9.8
46 bullous pemphigoid 9.8
47 chickenpox 9.8
48 molluscum contagiosum 9.8
49 dermatophytosis 9.8
50 cowpox 9.8

Graphical network of the top 20 diseases related to Contagious Pustular Dermatitis:



Diseases related to Contagious Pustular Dermatitis

Symptoms & Phenotypes for Contagious Pustular Dermatitis

Symptoms:

12
  • lesions on the finger

GenomeRNAi Phenotypes related to Contagious Pustular Dermatitis according to GeneCards Suite gene sharing:

26 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.97 FOXK1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.97 CYC1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.97 PRODH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.97 ELAVL2 FOXK1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.97 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.97 FOXK1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.97 FOXK1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.97 FOXK1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.97 FOXK1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.97 PRODH
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.97 ELAVL2 AKR7A2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.97 CYC1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 9.97 AKR7A2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.97 CYC1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.97 PRODH
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.97 CYC1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.97 FOXK1 PRODH AKR7A2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.97 CYC1 PRODH
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.97 PRODH
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.97 CYC1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.97 CYC1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.97 CYC1 AKR7A2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.97 PRODH

Drugs & Therapeutics for Contagious Pustular Dermatitis

Drugs for Contagious Pustular Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
2
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
3
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
6 Adrenergic Agents Phase 4
7 Antihypertensive Agents Phase 4
8 Neurotransmitter Agents Phase 4
9 Sympathomimetics Phase 4
10 Adrenergic alpha-Agonists Phase 4
11 Atomoxetine Hydrochloride Phase 4
12 Central Nervous System Stimulants Phase 4
13 Adrenergic Agonists Phase 4
14 Adrenergic alpha-2 Receptor Agonists Phase 4
15 Dopamine Uptake Inhibitors Phase 4
16 Autonomic Agents Phase 4
17 Peripheral Nervous System Agents Phase 4,Phase 1
18 Dopamine Agents Phase 4
19 adderall Phase 4
20 Neurotransmitter Uptake Inhibitors Phase 4
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 4,Phase 3
23
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
24
Vancomycin Approved Phase 3 1404-90-6 14969 441141
25
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
26
Iron Approved Phase 2, Phase 3 7439-89-6 23925
27
Camptothecin Experimental Phase 3 7689-03-4
28 Emollients Phase 3
29 Dermatologic Agents Phase 3,Phase 2
30 topoisomerase I inhibitors Phase 3
31 Antineoplastic Agents, Phytogenic Phase 3
32 Topoisomerase Inhibitors Phase 3
33 methicillin Phase 3
34 Iron Chelating Agents Phase 2, Phase 3
35 Chelating Agents Phase 2, Phase 3
36
Titanium dioxide Approved Phase 2 13463-67-7
37
Ethanol Approved Phase 2 64-17-5 702
38 Photosensitizing Agents Phase 2
39 Sunscreening Agents Phase 2
40 Radiation-Protective Agents Phase 2
41 Protective Agents Phase 2
42 Central Nervous System Depressants Phase 2,Phase 1
43 Anti-Infective Agents, Local Phase 2
44 Pharmaceutical Solutions Phase 2
45
Oxycodone Approved, Illicit, Investigational Phase 1 76-42-6 5284603
46 Analgesics Phase 1
47 Narcotics Phase 1
48 Analgesics, Opioid Phase 1
49
Methimazole Approved 60-56-0 1349907
50
Propylthiouracil Approved, Investigational 51-52-5 657298

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4 Methylphenidate;Mixed Salt Amphetamine;Atomoxetine;Guanfacine
2 Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules Recruiting NCT03502070 Phase 4 Placebo
3 Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis Completed NCT01084148 Phase 3 V0034CR01B;V0034CR01B vehicle
4 Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis Completed NCT01084720 Phase 3 V0034 CR
5 Irinotecan Versus Only Best Supportive Care for Gastric Cancer Completed NCT00144378 Phase 3 Irinotecan
6 A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients Recruiting NCT03181932 Phase 3 Vancomycin inhalation powder;Placebo inhalation powder
7 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
8 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU) Completed NCT00483496 Phase 2 Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209);Ti02 pigmentary 3% alone (formula RV3131A-MV1211);bisoctrizole 10% alone (formula RV3131A-MV1237);Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213);Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329);Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212);Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)];V0096 CR vehicle (formula RV3131A-MV1197)
9 Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. Completed NCT00462462 Phase 2 Ethanol 96% Gel;Ethanol 98% Solution
10 Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations Recruiting NCT03316560 Phase 1, Phase 2
11 Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients Completed NCT01160614 Phase 1 Oxycodone hydrochloride controlled-release (ORF) tablets
12 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis Recruiting NCT03626012 Phase 1 BIIB078;Placebo
13 The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors Unknown status NCT02419625 Not Applicable
14 Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism Unknown status NCT02812888 thionamide treatment for 3 months
15 Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348672
16 Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348633
17 Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity Unknown status NCT02148562
18 Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS Completed NCT02686268
19 Protocol TARC-ABPA Completed NCT01710930 Not Applicable
20 Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) Recruiting NCT03314207
21 Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) Recruiting NCT02590276 Not Applicable
22 Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects Recruiting NCT02372773
23 Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders Recruiting NCT01459302
24 OCT Angiography and NRAI in Dementia Recruiting NCT03761381
25 Study of Predictive Factors of Progression of Lateral Amyotrophic Sclerosis Recruiting NCT02360891
26 The Impact of Cranberries On the Microbiome and the Brain in Healthy Ageing sTudy (COMBAT) Recruiting NCT03679533 Not Applicable
27 The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study Recruiting NCT00317616
28 Cytokine Profile of Allergic Bronchopulmonary Aspergillosis Recruiting NCT03643185
29 Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation Active, not recruiting NCT01925196
30 Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS Not yet recruiting NCT03573466 Not Applicable

Search NIH Clinical Center for Contagious Pustular Dermatitis

Cochrane evidence based reviews: ecthyma, contagious

Genetic Tests for Contagious Pustular Dermatitis

Anatomical Context for Contagious Pustular Dermatitis

The Foundational Model of Anatomy Ontology organs/tissues related to Contagious Pustular Dermatitis:

19
Skin

MalaCards organs/tissues related to Contagious Pustular Dermatitis:

41
Skin, Testes, Liver

Publications for Contagious Pustular Dermatitis

Articles related to Contagious Pustular Dermatitis:

(show all 39)
# Title Authors Year
1
Pathogenicity of blood orf virus isolates in the development of dairy goat contagious pustular dermatitis. ( 29778194 )
2018
2
Isolation and molecular characterization of contagious pustular dermatitis virus from Rajasthan, India. ( 25674607 )
2014
3
Molecular and virological studies on contagious pustular dermatitis isolates from Egyptian sheep and goats. ( 20304450 )
2010
4
Orf: contagious pustular dermatitis. ( 20666089 )
2010
5
Orf (contagious pustular dermatitis) in farmworkers: prevalence and risk factors in three areas of England. ( 10452390 )
1999
6
Western blot analysis of virus-specific antibody responses for capripox and contagious pustular dermatitis viral infections in sheep. ( 7925674 )
1994
7
Contagious pustular dermatitis (orf) infection in sheep and goats in Saudi Arabia. ( 1909477 )
1991
8
Molecular analysis of contagious pustular dermatitis virus: a simplified method for viral DNA extraction from scab material. ( 1816256 )
1991
9
Detection of contagious pustular dermatitis virus of goats in a severe outbreak. ( 2588444 )
1989
10
Orf: contagious pustular dermatitis. ( 3179870 )
1988
11
Contagious pustular dermatitis (orf) of sheep affecting the ear following ear tagging. ( 3606509 )
1987
12
Human orf (ecthyma contagious) a report of two cases from Saudi Arabia. ( 21164240 )
1986
13
Contagious pustular dermatitis of sheep--possible confusion with vesicular diseases. ( 4004656 )
1985
14
Antigenic relationships among sheep pox, goat pox and contagious pustular dermatitis viruses. ( 6151351 )
1984
15
Prevalence of contagious pustular dermatitis (orf) in six million lambs at slaughter: a three-year study. ( 16030998 )
1983
16
Cross-neutralization tests on sheep pox, goat pox and contagious pustular dermatitis viruses. ( 90458 )
1979
17
Contagious pustular dermatitis of sheep in a veterinary student. ( 584593 )
1977
18
Cytopathogenicity of contagious pustular dermatitis virus in primary cell culture with special reference to the formation of intracytoplasmic inclusions. ( 4675558 )
1972
19
The vaccination of young lambs against contagious pustular dermatitis. ( 5555757 )
1971
20
Propagation of contagious pustular dermatitis virus in HeLa cell cultures. ( 5169601 )
1971
21
An outbreak of contagious pustular dermatitis associated with Dermatophilus congolensis infection. ( 5274960 )
1970
22
Possible &amp;quot;orf&amp;quot; (contagious pustular dermatitis, contagious ecthyma of sheep) infection in the dog. ( 5494712 )
1970
23
A case of orf (ecthyma contagiosum; contagious pustular dermatitis) contracted by a human from a wild Alaskan mountain goat. ( 4297665 )
1968
24
Growth of contagious pustular dermatitis virus in human tissue cultures. ( 14467780 )
1961
25
Studies with a strain of contagious pustular dermatitis virus in tissue culture. ( 14433531 )
1959
26
The immunological relations of the contagious pustular dermatitis virus to the mammalian pox group. ( 13596274 )
1958
27
Contagious pustular dermatitis. IV. Immunological reactions. ( 13502481 )
1958
28
Human infections with the virus of ovine contagious pustular dermatitis (scabby mouth). ( 13430966 )
1957
29
Contagious pustular dermatitis. II. Pathological histology. ( 13449179 )
1957
30
Contagious pustular dermatitis. III. Experimental infection. ( 13481166 )
1957
31
Contagious pustular dermatitis virus. I. Studies on morphology. ( 13416415 )
1957
32
Orf: contagious pustular dermatitis of sheep. ( 13361058 )
1956
33
Complement-fixation tests in the diagnosis of contagious pustular dermatitis infection in man. ( 14898387 )
1951
34
Human infection with the virus of contagious pustular dermatitis. ( 14814843 )
1951
35
The immunological relationship between a new virus, proliferative dermatitis of the legs (strawberry foot rot) of sheep, and the viruses of vaccinia and contagious pustular dermatitis. ( 18099893 )
1948
36
A case of orf; contagious pustular dermatitis; identification of the virus. ( 18123062 )
1948
37
The immunological relationships of strains of contagious pustular dermatitis virus. ( 20293732 )
1947
38
The relationship between the virus of contagious pustular dermatitis and a virus isolated from sheep papillomatosis by Selbie. ( 20293733 )
1947
39
Infection of man by the virus of contagious pustular dermatitis of sheep. ( 20279048 )
1946

Variations for Contagious Pustular Dermatitis

Expression for Contagious Pustular Dermatitis

Search GEO for disease gene expression data for Contagious Pustular Dermatitis.

Pathways for Contagious Pustular Dermatitis

GO Terms for Contagious Pustular Dermatitis

Biological processes related to Contagious Pustular Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 8.8 AKR7A2 CYC1 PRODH

Molecular functions related to Contagious Pustular Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 electron transfer activity GO:0009055 8.62 AKR7A2 CYC1

Sources for Contagious Pustular Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....